TY - JOUR
T1 - NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines
AU - Flaig, Thomas W.
AU - Spiess, Philippe E.
AU - Agarwal, Neeraj
AU - Bangs, Rick
AU - Boorjian, Stephen A.
AU - Buyyounouski, Mark K.
AU - Downs, Tracy M.
AU - Efstathiou, Jason A.
AU - Friedlander, Terence
AU - Greenberg, Richard E.
AU - Guru, Khurshid A.
AU - Hahn, Noah
AU - Herr, Harry W.
AU - Hoimes, Christopher
AU - Inman, Brant A.
AU - Jimbo, Masahito
AU - Kader, A. Karim
AU - Lele, Subodh M.
AU - Meeks, Joshua J.
AU - Michalski, Jeff
AU - Montgomery, Jeffrey S.
AU - Pagliaro, Lance C.
AU - Pal, Sumanta K.
AU - Patterson, Anthony
AU - Petrylak, Daniel P.
AU - Plimack, Elizabeth R.
AU - Pohar, Kamal S.
AU - Porter, Michael P.
AU - Preston, Mark A.
AU - Sexton, Wade J.
AU - Siefker-Radtke, Arlene O.
AU - Tward, Jonathan
AU - Wile, Geoffrey
AU - Johnson-Chilla, Alyse
AU - Dwyer, Mary A.
AU - Gurski, Lisa A.
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.
AB - The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.
UR - http://www.scopus.com/inward/record.url?scp=85053006866&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.0072
DO - 10.6004/jnccn.2018.0072
M3 - Review article
C2 - 30181416
AN - SCOPUS:85053006866
SN - 1540-1405
VL - 16
SP - 1041
EP - 1053
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -